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1. Introduction 
Aortic stenosis is the most frequent valvular heart disease in the western world and its 
incidence continues to rise. Until recently, aortic valve sclerosis (AVS) was considered to be a 
normal degenerative process associated with aging. For this reason, the common and well 
recognized soft, basal ejection murmur of aortic sclerosis was generally regarded by physicians 
to be of little or no clinical significance. In the last decade, AVS has been the focus of both 
clinical and animal research. AVS has emerged as a biomarker for cardiovascular risk, and 
ultimately leads to aortic stenosis in 16% of adults (Stewart et al., 1997; Cosmi et al., 2002). 
Calcific aortic valve disease ranges from aortic sclerosis, defined as focal, irregular 
thickening of aortic valve leaflets with no hemodynamically significant derangement (i.e., 
peak velocity of ≤ 2 m/s and no significant aortic regurgitation), to severe calcification (with 
impaired leaflet motion and an aortic jet velocity of  ≥ 2.5 m/s) referred to as aortic stenosis. 
The paradigm of aortic stenosis has shifted from being considered a degenerative aging 
process; it is now recognized as a dynamic inflammatory process with features similar to 
atherosclerotic plaque. These features include endothelial disruption, focal deposition of low 
density lipoprotein (LDL) cholesterol and lipoprotein A, accumulation of macrophages and 
T lymphocytes, and calcification (Freeman et al., 2004). 
2. Epidemiology and etiology 
Aortic valve sclerosis is present in approximately 25% of people 65 to 74 years old and in 50 
% of people over 84 years (Lindroos et al., 1993; Stewart et al., 1997; Otto et al., 1999), while  
aortic stenosis affects 2% of  the population over  65 years old, 3 % over  75 years old, and 
4% over 85 years old (Stewart, 1997). The severity of aortic sclerosis on a scale of 0-3 has 
been quantified by echocardiography for echogenicity, thickening, or calcification of the 
valve leaflet as follows (Chandra et al., 2004): 
• 0- Normal (No involvement) 
• 1- Mild (Minor involvement of one leaflet) 
• 2- Moderate (Minor involvement of two leaflets or extensive involvement of one leaflet) 
• 3- Severe (Extensive involvement of two leaflets or involvement of all three leaflets) 
In adults, valvular aortic stenosis is due to degenerative calcific changes of a trileaflet valve, 
rheumatic disease, or secondary calcification of a congenitally bicuspid valve (Roberts, 1970; 
Selzer, 1987). In developed countries, the most common cause of adult acquired aortic 
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stenosis at present is a chronic inflammatory and fibrotic process of the aortic valve very 
similar to atherosclerosis. Histologically, the valve consists of 3 layers: [1] the ventricularis 
(on the ventricular side of the leaflet), composed of elastin rich fibers; [2] the fibrosa (on the  
aortic side of leaflet), composed of fibroblasts and collagen fibres; and [3] the spongiosa (at 
the base of leaflet, between the fibrosa and ventricularis), a layer of loose connective tissue  
composed of fibroblasts, mesenchymal cells, and mucopolysaccharide- rich matrix. 
Progressive fibrosis and calcification can occur on a bileaflet or a trileaflet valve; it occurs 
earlier in life in the bicuspid valve. The most common cause of aortic stenosis in patients 65 
years old and over is called "senile calcific aortic stenosis". With aging, the protein collagen 
of the valve leaflets is destroyed, and calcium is deposited on the leaflets. Turbulence across 
the valve increases, which causes scarring, thickening, and stenosis of the valve once valve 
leaflet mobility is reduced by calcification.  
Rheumatic fever is the cause of aortic stenosis in developing countries. Rheumatic 
involvement of the aortic valve is characterized by commissural fusion between the aortic 
valve leaflets. When rheumatic fever is the cause of aortic stenosis, the mitral valve is also 
affected in most patients (Campbell, 1968). 
3. Clinical presentation 
The classic triad of symptoms in significant aortic stenosis is angina, syncope, and dyspnea, 
all of which typically occur with exertion. Occasionally, gastrointestinal bleeding occurs 
secondary to arteriovenous malformations, platelet dysfunction, and defective coagulation 
in what is termed as Heyde syndrome (Zigelman et al., 2009; Batur et al., 2003; Sucker, 2007). 
In older adults, symptoms are often delayed due to an age- associated decrease in activity, 
and symptom are attributed to other conditions  common in the elderly; therefore,  special 
attention should be focused on the elicitation of symptoms. 
Angina is the first symptom in one-third of the patients, and it eventually occurs in one-half 
of patients with aortic stenosis. It is due to a supply and demand mismatch caused by a 
combination of left ventricular hypertrophy, increased afterload, increased wall strain, and 
excessive compression of the coronary arteries. Syncope related to aortic stenosis is usually 
associated with exertion or excitement. These conditions cause vasodilation and lowering of 
blood pressure. In aortic stenosis, the heart is unable to increase cardiac output due to fixed 
left ventricular outflow tract (LVOT) obstruction, and is unable to compensate for the drop 
in blood pressure. This results in decreased cerebral perfusion, thereby causing syncope. 
Dyspnea is a late- presenting symptom of severe aortic stenosis caused by failure of the left 
ventricle to compensate for the outflow obstruction. 
On physical examination, the hallmark of aortic stenosis is a late peaking crescendo-
decrescendo systolic murmur. It is best heard at the upper- right or left- sterna border, 
radiating to the carotids. Older adults exhibit certain variations of this characteristic pattern. 
The occurrence of heart failure and chronic lung disease common in this population results 
in a significant reduction in the intensity of the murmur, while pure aortic sclerosis without 
stenosis may present with an apical systolic high- pitched murmur (Gallavardin phenomenon) 
(Hage et al., 2011). 
4. Risk factors 
Several lines of evidence suggest that, in addition to the pathophysiological similarities to 
atherosclerosis, aortic stenosis and coronary disease share many risk factors, such as male 
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gender, older age group, tobacco use, diabetes mellitus, hypercholesterolemia, hypertension, 
hyperparathyroidism, renal disease, decreased bone density, and metabolic syndrome 
(Figure 1). Increased C-reactive protein (CRP) as a risk factor for aortic stenosis is 
controversial. Reports from a few studies show a positive association between aortic stenosis 
and increased CRP; however, a recent prospective trial (Novaro et al., 2007)  involving 5621 
subjects followed over a period of 5 years, and using echocardiography and CRP 
measurements, showed that there was no association between CRP and  the development of 
aortic stenosis. In addition, being Caucasian and short in stature were found to have a 
positive association with development of aortic stenosis.  
 
 
Fig. 1. Schematic view of risk factors involved in aortic valve disease 
5. Pathogenesis 
5.1 Early lesion 
The early sclerotic lesion shows focal subendothelial plaque like lesions on the aortic surface 
of the leaflet that extends into the adjacent fibrosa layer. The initiating factor for these 
lesions is the endothelial disruption due to increased mechanical or decreased shear stress. 
The Mechanical stress of the aortic valve is highest on the aortic side of the leaflet in the 
flexion area. These lesions show similarities to atherosclerosis, with a prominent accumulation 
of atherogenic lipoproteins, low density lipoprotein (LDL) oxidation, inflammatory cell 
infiltrate, and microcalcification (O'Brien et al., 1996; Olsson et al., 1999; Otto et al., 1994). 
5.2 Inflammation and lipoproteins 
Over the course of time, mechanical stress leads to endothelial dysfunction, which is then 
perpetuated by inflammatory cell infiltrate consisting of both T-lymphocytes and 
macrophages. Monocytes infiltrate the endothelium and differentiate into macrophages via 
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adhesion molecules (Ghaisas et al., 2000). After infiltrating into the endothelium, these 
inflammatory cells upregulate inflammatory cytokines, transforming growth factor, and 
interleukin, all of which act on valvular fibroblasts and promote cellular proliferation, 
extracellular matrix remodeling, and local calcification. Focal, extracellular lipid 
accumulation is seen within each valve leaflet, in small areas in the subendothelial region, 
with displacement of elastic lamina and extension into adjacent fibrosa (Otto et al., 1994). 
LDL that is taken into the subendothelial layer undergoes oxidative modification and 
subsequent macrophage ingestion to become foam cells. Studies have shown that aortic 
stenosis is associated with high levels of plasma asymmetric dimethylarginine, a marker of 
endothelial dysfunction (Ngo et al., 2007) and that nitric oxide (NO) is involved in inhibiting 
valve calcification (Kennedy et al., 2009).  Aortic sclerosis has been associated with NO 
resistance in platelets, which explains the thrombotic risk in patients with aortic sclerosis 
(Ngo et al., 2009). 
5.3 Angiotensin converting enzyme and extracellular matrix 
Angiotensin converting enzyme(ACE) has been identified in aortic sclerotic lesions(O'Brien 
et al., 2002).There is evidence that the majority of this enzyme is extracellular  and co-
localized with apolipoprotein B, even though some of it may be locally produced. The aortic 
valve is exposed to pulsatile repetitive pressure and shear stress during systole, whereas 
cyclical stretch and turbulent shear stress occur during diastole. These are transmitted to 
valve interstitial cells (VICs) by endothelial cells and the matrix (Sacks et al., 2007), which 
results in cell proliferation, increased collagen deposition, apoptosis, and enhanced 
cathepsin S and K expression. Furthermore, increased cyclic stretch increases the expression 
and activity of matrix metalloproteinase (MMP)-1, 2, and 9, whereas it reduces the 
expression as well as the activity of cathepsin L and tissue inhibitor of metalloproteinase-1 
(TIMP-1) (Balachandran et al., 2009). In patients with aortic stenosis and coronary artery 
disease, an increase in soluble vascular cell adhesion molecule-1 (VCAM-1) occurs along 
with a decrease in soluble intercellular adhesion molecule-1 (ICAM-1) and s-E selectin 
(Linhartova et al., 2009). Increased expression of elastolytic cathepsins S, K, and V and their 
inhibitor cystatin C is also observed (Helske et al., 2006). The association of calcific aortic 
valve disease and increase in endothelin-1 and endothelin A receptor support the evidence 
of inflammation and fibrosis in aortic calcific disease (Peltonen et al., 2009). 
5.4 Angiogenesis and osteogenesis 
As the disease progresses, active bone formation is seen. Angiogenesis is predominant in the 
pathogenesis of aortic stenosis and is the hallmark for longitudinal bone growth. 
Angiogenetic factors such as vascular endothelial growth factor (VEGF) have been shown to 
be necessary for enchondral bone formation in calcified valves (Gerber et al., 1999).The 
lipids and inflammatory cells localize within the microscopic calcific areas, which results in 
macrophage- derived osteopontin, a key element in tissue calcification (Abdel-Azeez et al., 
2010).Synthesis of bone sialoprotein, tenacin C and extracellular matrix proteins also 
ensues(Kaden et al., 2003; Satta et al., 2002; Kaden et al., 2004).There is evidence that native 
aortic valve disease involves mediators of bone homeostasis like osteoprotegrin (OPG), 
receptor activator of nuclear factor κ B (RANK), and receptor activator of nuclear factor κ B 
ligand (RANKL), and that OPG/RANKL ratio was less in stenotic than in  sclerotic valves 
(Steinmetz et al., 2008). 
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5.5 Genetics 
Genetic factors may be important in the development of aortic valve calcification. Genetic 
polymorphism of interlukin 10, connective tissue growth factor, chemokine receptor 5, 
apoprotein polymorphism, and estrogen receptors have been shown to influence valvular 
calcification (Ortlepp et al., 2004). In addition, the B allele of vitamin D receptor has an 
association with aortic valve stenosis, which confirms the abnormal bone signaling pathway 
in the pathogenesis of the disease (Ortlepp et al., 2001). Another finding that implies the role 
of genetics in aortic valve disease is the loss of function mutation of Notch 1 receptor in 
patients with aortic stenosis (Garg et al., 2005). 
 
CRP 
Adhesion 
molecules  
Calcium
Tenascin-C
VEGF
TGFß
Cystatin C
Osteopontin
Osteonectin
RANKL/OPG 
BMP
MMP 
Cathepsin
Inflammation Angiogenesis Osteogenesis ECM remodelling
Aortic Valve 
Calcification
 
CRP: C-reactive protein; VEGF: Vascular endothelial growth factor; TGF: Transforming growth factor; 
RANKL: Receptor activator of nuclear factor κ B ligand; OPG: Osteoprotegerin; BMP: Bone morphogenetic 
protein; MMP: Matrix Metalloproteinase 
Fig. 2. Schematic view of mediators in pathogenesis of aortic valve calcification 
6. Animal models 
Several elegant animal studies have advanced the pathogenetic understanding of aortic 
valve disease. Rajamannan et al. (2001) compared the aortic valves in rabbits fed on a high 
cholesterol diet to those fed on a standard diet. The microscopy of the hypercholesterolemia 
rabbits demonstrated a cholesterol infiltrative pattern along with low- grade apoptosis, 
neither of which was seen in the control rabbits.  Furthermore, Rajamannan et al. (2005a) 
showed that aortic valves from hypercholesterolemic rabbits had evidence of atherosclerotic 
streaks, increased CRP, early calcification, and minor levels of nitric oxide synthase (eNOS) 
compared with controls. The rabbits treated with atorvastatin had less lipid accumulation 
and higher levels of eNOS. More recently (Rajamannan et al., 2005b), aortic valve 
calcification was shown to be similar to osteogenesis with a similar spectroscopic 
appearance and bone matrix markers (osteopontin, bone sialoprotein, osteocalcin) with 
increase in low-density receptor- related protein (Lrp5) using models fed on a cholesterol 
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Authur 
(Year) 
Population(N)/
Age (Years) 
Outcome Measures Conclusion 
Ngo  
et al. (2009) 
n=253; 51-77 Transthoracic Echo,  
AVBS score 
Association of platelet NO 
resistance with aortic 
sclerosis 
Linhartova  
et al. (2009) 
n=223; Coronary angiography, 
Echo 
Association of  
aortic stenosis with  
s-VCAM1 in CAD pts 
Peltonen  
et al. (2009) 
n=36; 58± 6 Immunohistochemistry,  
RT-PCR 
Upregulation of ET1 & ETA 
receptor in aortic stenosis 
Abdel-Azeez  
et al. (2010) 
n=120 OPN & hsCRP 
measurement, coronary 
angio, Echo, lipid profile 
OPN is an independent 
factor of aortic sclerosis 
Steinmetz  
et al. (2008) 
n=69 Immunostaining, 
Morphometry 
OPG/RANKL/RANK 
system is involved in aortic 
valve calcification 
Ortlepp  
et al. (2001) 
n=200 Restricted fragment length  
polymorphism, PCR 
Association of aortic 
stenosis with Vitamin D 
receptor genotype 
Garg  
et al. (2005) 
n=14 DNA collection, luciferase 
assay, PCR, Phenotypic 
evaluation, Genetic linkage 
analysis 
NOTCH 1 mutation causes 
early defect in aortic valve 
& calcium deposition 
Echo, Echocardiography; Angio, Angiography; RT-PCR, Reverse transcriptase-Polymerase chain reaction; AVBS, 
Aortic valve ultrasonic back scatter; NO, nitric oxide. 
Table 1. Description of human studies 
diet and atorvastatin. In addition, intervention with a statin showed a reduction in bone 
formation, less cellular proliferation, a lower Lrp5/beta catenin protein level, and an 
increase in endothelial NO synthase concentration (Rajamannan et al., 2005a, 2005b). 
Recently it was shown (Barrick et al., 2009)  that epidermal growth factor receptor (EGFR) 
signaling contributes to normal valvulogenesis and that reduced EGFR was associated with 
aortic stenosis in mice models. Another mouse- model study (Matsumoto et al., 2010) 
showed the beneficial effect of regular exercise training in preventing aortic sclerosis by 
various pathways, e.g., reducing inflammation and oxidative stress, inhibiting osteogenic 
pathway, and maintaining endothelial integrity. Various studies suggest that vitamin D and 
an  atherogenic diet induce aortic stenosis only when they act in combination (Drolet et al., 
2008), and that an association of aortic valve stenosis and tissue factor was demonstrated 
(Marechaux et al., 2009). 
7. Treatment 
Accumulating animal and human studies suggest that aortic sclerosis is an inflammatory 
disease akin to atherosclerosis in addition to being an important biomarker of 
atherosclerosis and coronary artery disease. It is a slowly progressive disease that leads to 
aortic stenosis and, therefore, should be treated aggressively.  
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Authur 
(Year) 
Model 
(N) 
Intervention Outcome 
Measures 
Follow Up Conclusion 
Rajamannan 
et al. (2001) 
Rabbits; 
n=16 
Cholesterol AV dissection 12 weeks Aortic valve 
apoptosis 
Rajamannan 
et al. (2005) 
Rabbits; 
n=48 
Cholesterol, 
Atorvastatin 
eNOS 
expression, 
Western blot, 
Micro CT 
3 months Hypercholester-
olemia produces 
bone mineralization 
in AV. Atorvastatin 
inhibits AVC & 
increases eNOS 
concentration 
Rajamannan 
et al. (2005) 
Rabbits; 
n= 54 
Cholesterol, 
Atorvastatin 
Micro CT, 
Calcein inj, 
Osteopontin 
expression 
24 weeks Positive bone 
formation in calcific 
AV but atorvastatin 
attenuates it. 
Barrick et al. 
(2009)  
Egfr-null 
mice; 
n=119 
 None Echo, 
Histology, gene 
expression, 
Ventricular 
pressure 
 15months EGFR is required 
for valvulogenesis 
& decreased EGFR 
is seen in AS 
Matsumoto 
et al. (2010) 
Mice; 
n=94 
Cholesterol, 
regular ET, 
Occasional 
ET 
Histologic 
analysis, 
Immunohistoch
emistry 
16 weeks Regular ET 
prevents AV 
sclerosis 
Drolet et al. 
(2008) 
Rabbits Cholesterol, 
Vitamin D 
Transvalvular 
gradient, AVA, 
Immunohistolo
gical study, 
Echo 
12 weeks Atherosclerosis & 
calcifying factors 
induce AS in 
combination 
Marechauxs 
et al. (2009) 
Rabbits; 
n= 45 
Cholesterol, 
Vitamin D 
Immunohistolo
gy, Doppler AV 
performance, 
Histology 
12 weeks Association of AV 
sclerosis with tissue 
factor 
REF, Reference; eNOS, Endothelial nitric oxide synthase; CT, Computed tomography; AV, Aortic valve; 
AVC, Aortic valve calcification; EGFR, Epidermal growth factor receptor; ET, Exercise training; AVA, 
Aortic valve area; Echo, Echocardiography; Inj, Injection. 
Table 2. Description of animal model   
7.1 Pharmacological therapy 
Statins are known pleiotropic drugs with an anti-inflammatory and antioxidant effect in 
addition to their ability to lower  lipid levels, stabilize, plaque, and  prevent platelet 
aggregation. This underscores their role in preventing atherosclerotic vascular disease. With 
cumulative evidence on the similarities between vascular atherosclerosis and aortic valve 
disease, the hypothesis that statins halt the progression of aortic sclerosis to stenosis was 
proposed. Statins and ACE-I were considered the first-line candidates for slowing down  the 
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Authur 
(Year) 
Population(N)
/Age (Years) 
Intervention Outcome 
Measures 
Study 
Type 
Conclusion 
Antonini-
Canterin  
et al. (2008) 
n=1046;  
70±8 
Statins Echocardiogram Retro-
spective 
Statins were 
effective in 
aortic sclerosis 
& mild stenosis. 
Shavelle  
et al. (2002) 
n=65;  
67-68 (mean) 
Statins Electron beam 
computed 
tomogram 
Retro-
spective 
Statins reduce 
aortic valve 
calcium 
accumulation. 
Bellamy  
et al. (2002) 
n=156;  
77±12 
Statins Doppler 
echocardiogram 
Pro-
spective 
Statin therapy 
results in slower 
progression of 
AS. 
Moura  
et al. (2007) 
n=121;  
73±8.9 
Rosuvastatin Echo, serum 
lipids & 
inflammatory 
markers 
Pro-
spective 
Rosuvastatin 
20mg is 
beneficial in 
slowing AS 
progression 
Cowell  
et al. 
(SALTIRE) 
(2005) 
n=155 Atorvastatin 
80mg 
Doppler 
Echocardiogram, 
Helical CT 
Double- 
blinded 
rando-
mized 
Statins do not 
halt the AS 
progression 
Rossebo  
et al. 
(SEAS) 
(2008) 
n=1873;  
68±10 
Simvastatin 
10mg,  
Ezetimbe  
40mg 
Cardiovascular 
events, nonfatal 
MI 
Double-
blinded 
rando-
mized 
Simvastatin and 
ezetimibe did 
not reduce the 
composite 
outcome of 
combined aortic-
valve events and 
ischemic events 
in patients with 
aortic stenosis 
Chan et al. 
(ASTRON
OMER) 
(2010) 
N=269; Rosuvastatin 
40 mg 
Echocardiogram Double- 
blinded 
rando-
mized 
Rosuvastatin 
did not reduce 
progression of 
AS 
Hamilton 
et al. (2011) 
Rabbits Cholesterol, 
statins 
MRI, Excised  
AV tissue 
thickness, lipid 
accumulation 
Pro-
spective 
In advance 
stages of AS, 
statin therapy is 
ineffective 
REF, Reference; AS, Aortic stenosis; CT, Computed tomography; MI, Myocardial infarction; MRI, 
Magnetic resonance imaging 
Table 3. Description of statin studies 
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progression of aortic sclerosis and mild aortic stenosis (Antonini-Canterin et al., 2008; 
Shavelle et al., 2002; Bellamy et al., 2002), but not for moderate-to-severe stenosis. Moura et 
al. (2007), in a 1.5-year prospective study, were the first to show the positive effect of statins 
in slowing the progression of aortic stenosis. Contrary evidence from three prospective 
randomized trials suggests that statins do not slow the progression of aortic valve disease 
but lower cholesterol and thus reduce coronary events. The three trials were SALTIRE (The 
Scottish Aortic Stenosis and Lipid Lowering Trial), SEAS (Simvastatin and Ezetimbe in 
Aortic Stenosis), and ASTRNOMER (Aortic Stenosis Progression Observation Measuring 
Effects of Rosuvastatin), which involved 155, 1873 and 269 participants, respectively (Cowell 
et al., 2005; Rossebo et al., 2008; Chan et al., 2010). In a recent animal experiment with rabbits 
(Hamilton et al., 2011), it was shown that statin therapy did not regress the disease process 
in valves with established sclerosis. Thus, medical intervention at an early stage of aortic 
sclerosis or trivial stenosis may be beneficial, but large outcome- based studies are lacking. 
8. Conclusion 
Aortic stenosis is the most common valvular pathology in older adults. It is emerging with 
increasing clarity that aortic valve sclerosis is an active inflammatory process and may be 
construed as a cardiovascular disease risk biomarker. Physicians should no longer ignore 
the murmur of aortic sclerosis as innocent; rather, it should be a beacon alerting us of the 
dangers that lie ahead for patients who harbor this murmur. 
It is also evident that aortic sclerosis progresses to aortic stenosis.  In fact, this progression is 
not infrequent. The take- home message from the larger trials and natural history studies 
seems to be that the target for therapy in established, calcific aortic stenosis may be too late, 
and that early, aggressive medical intervention be undertaken before the irrevocable process 
of calcification has occurred. Future studies are needed to fully estimate the benefits of 
medical therapy as well as the optimal timing for such interventions. Newer therapeutic 
options targeting the molecular and cellular mechanisms involved in the pathogenesis of 
aortic valve disease either singularly or in concert are needed. 
9. References   
Abdel-Azeez, H. A., Al-Zaky, M. (2010). Plasma osteopontin as a predictor of coronary 
artery disease: association with echocardiographic characteristics of atherosclerosis. 
J Clin Lab Anal, 24(3): 201-206. 
Antonini-Canterin, F., Hirsu, M., Popescu, B. A., et al. (2008). Stage-related effect of statin 
treatment on the progression of aortic valve sclerosis and stenosis. Am J Cardiol, 
102(6): 738-742. 
Balachandran, K., Sucosky, P., Jo, H., et al. (2009). Elevated cyclic stretch alters matrix 
remodeling in aortic valve cusps: implications for degenerative aortic valve disease. 
Am J Physiol Heart Circ Physiol, 296(3): H756-764. 
Barrick, C. J., Roberts, R. B., Rojas, M., et al. (2009). Reduced EGFR causes abnormal valvular 
differentiation leading to calcific aortic stenosis and left ventricular hypertrophy in 
C57BL/6J but not 129S1/SvImJ mice. Am J Physiol Heart Circ Physiol, 297(1): H65-
75. 
Batur, P., Stewart, W. J., Isaacson, J. H. (2003). Increased prevalence of aortic stenosis in 
patients with arteriovenous malformations of the gastrointestinal tract in Heyde 
syndrome. Arch Intern Med, 163(15): 1821-1824. 
www.intechopen.com
 
Aortic Valve 
 
130 
Bellamy, M.F., Pellikka, P.A., Klarich, K.W., et al. (2002). Association of cholesterol levels, 
hydroxymethylglutaryl coenzyme-A reductase inhibitor treatment, and progression 
of aortic stenosis in the community. J Am Coll Cardiol, 40(10): 1723-1730. 
Campbell, M. (1968). Calcific aortic stenosis and congenital bicuspid aortic valves. Br Heart 
J, 30(5): 606-616. 
Chan, K.L., Teo, K., Dumesnil, J.G., et al. (2010). Effect of Lipid lowering with rosuvastatin 
on progression of aortic stenosis: results of the aortic stenosis progression 
observation: measuring effects of rosuvastatin (ASTRONOMER) trial. Circulation, 
121(2): 306-314. 
Chandra, H. R., Goldstein, J.A., Choudhary, N., et al. (2004). Adverse outcome in aortic 
sclerosis is associated with coronary artery disease and inflammation. J Am Coll 
Cardiol, 43(2): 169-175. 
Cosmi, J.E., Kort, S., Tunick, P.A., et al. (2002). The risk of the development of aortic stenosis 
in patients with "benign" aortic valve thickening. Arch Intern Med, 162(20): 2345-
2347. 
Cowell, S.J., Newby, D.E., Prescott, R.J., et al. (2005). A randomized trial of intensive lipid-
lowering therapy in calcific aortic stenosis. N Engl J Med, 352(23): 2389-2397. 
Drolet, M.C., Couet, J., Arsenault, M. (2008). Development of aortic valve sclerosis or 
stenosis in rabbits: role of cholesterol and calcium. J Heart Valve Dis, 17(4):  381-
387. 
Freeman, R.V., Crittenden, G., Otto, C. (2004). Acquired aortic stenosis. Expert Rev 
Cardiovasc Ther, 2(1): 107-116. 
Garg, V., Muth, A.N., Ransom, J.F., et al. (2005). Mutations in NOTCH1 cause aortic valve 
disease. Nature, 437(7056): 270-274. 
Gerber, H. P., Vu, T. H., Ryan, A. M., et al. (1999). VEGF couples hypertrophic cartilage 
remodeling, ossification and angiogenesis during endochondral bone formation. 
Nat Med, 5(6): 623-628. 
Ghaisas, N. K., Foley, J. B., O'Briain, D. S., et al.  (2000).Adhesion molecules in nonrheumatic 
aortic valve disease: endothelial expression, serum levels and effects of valve 
replacement. J Am Coll Cardiol, 36(7): 2257-2262. 
Hage, F. G., Adegunsoye, A., Mundkur, M., et al. (2011). The role of echocardiography in the 
evaluation and management of aortic stenosis in the older adult. Int J Cardiol. 
Hamilton, A. M., Boughner, D. R., Drangova, M., et al. (2011). Statin treatment of 
hypercholesterolemic-induced aortic valve sclerosis. Cardiovasc Pathol, 20(2): 84-
92. 
Helske, S., Syvaranta, S., Lindstedt, K.A., et al. (2006). Increased expression of elastolytic 
cathepsins S, K, and V and their inhibitor cystatin C in stenotic aortic valves. 
Arterioscler Thromb Vasc Biol, 26(8): 1791-1798. 
Kaden, J. J., Bickelhaupt, S., Grobholz, R., et al. (2004). Expression of bone sialoprotein and 
bone morphogenetic protein-2 in calcific aortic stenosis. J Heart Valve Dis, 13(4): 
560-566. 
Kaden, J. J., Dempfle, C. E., Grobholz, R., et al. (2003). Interleukin-1 beta promotes matrix 
metalloproteinase expression and cell proliferation in calcific aortic valve stenosis. 
Atherosclerosis, 170(2): 205-211. 
Kennedy, J. A., Hua, X., Mishra, K., et al. (2009). Inhibition of calcifying nodule formation in 
cultured porcine aortic valve cells by nitric oxide donors. Eur J Pharmacol, 602(1): 
28-35. 
www.intechopen.com
 
The Progression of Aortic Sclerosis to Aortic Stenosis 
 
131 
Lindroos, M., Kupari, M., Heikkila, J., et al. (1993). Prevalence of aortic valve abnormalities 
in the elderly: an echocardiographic study of a random population sample. J Am 
Coll Cardiol, 21(5): 1220-1225. 
Linhartova, K., Sterbakova, G., Racek, J., et al.  (2009). Linking soluble vascular adhesion 
molecule-1 level to calcific aortic stenosis in patients with coronary artery disease. 
Exp Clin Cardiol, 14(3): e80-83. 
Marechaux, S., Corseaux, D., Vincentelli, A., et al.(2009). Identification of tissue      factor in 
experimental aortic valve sclerosis. Cardiovasc Pathol, 18(2): 67-76. 
Matsumoto, Y., Adams, V., Jacob, S., et al. (2010). Regular exercise training prevents aortic 
valve disease in low-density lipoprotein-receptor-deficient mice. Circulation, 
121(6): 759-767. 
Moura, L. M., Ramos, S. F., Zamorano, J. L., et al. (2007).Rosuvastatin affecting aortic valve 
endothelium to slow the progression of aortic stenosis. J Am Coll Cardiol, 49(5): 
554-561. 
Ngo, D. T., Heresztyn, T., Mishra, K., et al. (2007). Aortic stenosis is associated with elevated 
plasma levels of asymmetric dimethylarginine (ADMA). Nitric Oxide, 16(2): 197-
201. 
Ngo, D. T., Sverdlov, A. L., Willoughby, S. R., et al. (2009). Determinants of occurrence of 
aortic sclerosis in an aging population. JACC Cardiovasc Imaging, 2(8): 919-927. 
Novaro, G. M., Katz, R., Aviles, R. J., et al. (2007). Clinical factors, but not C-reactive protein, 
predict progression of calcific aortic-valve disease: the Cardiovascular Health 
Study. J Am Coll Cardiol, 50(20): 1992-1998. 
O'Brien, K. D., Reichenbach, D. D., Marcovina, S. M., et al. (1996). Apolipoproteins B, (a), 
and E accumulate in the morphologically early lesion of 'degenerative' valvular 
aortic stenosis. Arterioscler Thromb Vasc Biol, 16(4): 523-532. 
O'Brien, K. D., Shavelle, D. M., Caulfield, M. T., et al. (2002).Association of angiotensin-
converting enzyme with low-density lipoprotein in aortic valvular lesions and in 
human plasma. Circulation, 106(17): 2224-2230. 
Olsson, M., Thyberg, J., Nilsson, J. (1999).Presence of oxidized low density lipoprotein in 
nonrheumatic stenotic aortic valves. Arterioscler Thromb Vasc Biol, 19(5): 1218-
1222. 
Ortlepp, J. R., Hoffmann, R., Ohme, F., et al. (2001).The vitamin D receptor genotype 
predisposes to the development of calcific aortic valve stenosis. Heart, 85(6): 635-
638. 
Ortlepp, J. R., Schmitz, F., Mevissen, V., et al. (2004). The amount of calcium-deficient 
hexagonal hydroxyapatite in aortic valves is influenced by gender and associated 
with genetic polymorphisms in patients with severe calcific aortic stenosis. Eur 
Heart J, 25(6): 514-522. 
Otto, C. M., Kuusisto, J., Reichenbach, D. D., et al.  (1994). Characterization of the early 
lesion of 'degenerative' valvular aortic stenosis. Histological and 
immunohistochemical studies. Circulation, 90(2): 844-853. 
Otto, C. M., Lind, B.K., Kitzman, D. W., et al.  (1999). Association of aortic-valve sclerosis 
with cardiovascular mortality and morbidity in the elderly. N Engl J Med, 341(3): 
142-147. 
Peltonen, T., Taskinen, P., Napankangas, J., et al. (2009).Increase in tissue endothelin-1 and 
ETA receptor levels in human aortic valve stenosis. Eur Heart J, 30(2): 242-249. 
www.intechopen.com
 
Aortic Valve 
 
132 
Rajamannan, N. M., Sangiorgi, G., Springett, M., et al. (2001). Experimental 
hypercholesterolemia induces apoptosis in the aortic valve. J Heart Valve Dis, 10(3): 
371-374. 
Rajamannan, N.M., Subramaniam, M., Caira, F., et al. (2005). Atorvastatin inhibits 
hypercholesterolemia-induced calcification in the aortic valves via the Lrp5 
receptor pathway. Circulation, 112(9 Suppl): I229-234. 
Rajamannan, N. M., Subramaniam, M., Stock, S. R., et al. (2005). Atorvastatin inhibits 
calcification and enhances nitric oxide synthase production in the 
hypercholesterolaemic aortic valve. Heart, 91(6): 806-810. 
Roberts, W. C. (1970).  Anatomically isolated aortic valvular disease. The case against its 
being of rheumatic etiology. Am J Med, 49(2): 151-159. 
Rossebo, A. B., Pedersen, T. R., Boman, K., et al. (2008). Intensive lipid lowering with 
simvastatin and ezetimibe in aortic stenosis. N Engl J Med, 359(13): 1343-1356. 
Sacks, M. S., Yoganathan, A. P. (2007). Heart valve function: a biomechanical perspective. 
Philos Trans R Soc Lond B Biol Sci, 362(1484): 1369-1391. 
Satta, J., Melkko, J., Pollanen, R., et al. (2002). Progression of human aortic valve stenosis is 
associated with tenascin-C expression. J Am Coll Cardiol, 39(1): 96-101. 
Selzer, A. (1987). Changing aspects of the natural history of valvular aortic stenosis. N Engl J 
Med, 317(2): 91-98. 
Shavelle, D. M., Takasu, J., Budoff, M. J., et al. (2002). HMG CoA reductase inhibitor (statin) 
and aortic valve calcium. Lancet, 359(9312): 1125-1126. 
Steinmetz, M., Skowasch, D., Wernert, N., et al. (2008). Differential profile of the 
OPG/RANKL/RANK-system in degenerative aortic native and bioprosthetic 
valves. J Heart Valve Dis, 17(2): 187-193. 
Stewart, B. F., Siscovick, D., Lind, B. K., et al. (1997). Clinical factors associated with calcific 
aortic valve disease. Cardiovascular Health Study. J Am Coll Cardiol, 29(3): 630-
634. 
Sucker, C. (2007). The Heyde syndrome: proposal for a unifying concept explaining the 
association of aortic valve stenosis, gastrointestinal angiodysplasia and bleeding. 
Int J Cardiol, 115(1): 77-8. 
Zigelman, C. Z., Edelstein, P. M. (2009). Aortic valve stenostenosis. Anesthesiol Clin, 27(3): 
519-532, table of contents 
www.intechopen.com
Aortic Valve
Edited by Prof. Chen Ying-Fu
ISBN 978-953-307-561-7
Hard cover, 350 pages
Publisher InTech
Published online 09, December, 2011
Published in print edition December, 2011
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
Much has evolved in the field of aortic valve disease because of the increase in knowledge in the last decade,
especially in the area of its management. This book "Aortic Valve" is comprised of 18 chapters covering basic
science, general consideration of aortic valve disease, infective endocarditis, aortic sclerosis and aortic
stenosis, bioprosthetic valve, transcatheter aortic valve implantation and a special section on congenital
anomalies of the aortic valve. We hope this book will be particularly useful to cardiologists and cardiovascular
surgeons and trainees. We also believe that this book will be a valuable resource for radiologists, pathologists,
cardiovascular anesthesiologists, and other healthcare professionals who have a special interest in treating
patients with aortic valve disease. We are certain that information in this book will help to provide virtually most
new areas of aortic valve disease that will be employed in the current era.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Uzma Jalal Serageldin Raslan and Farouk Mookadam (2011). The Progression of Aortic Sclerosis to Aortic
Stenosis, Aortic Valve, Prof. Chen Ying-Fu (Ed.), ISBN: 978-953-307-561-7, InTech, Available from:
http://www.intechopen.com/books/aortic-valve/the-progression-of-aortic-sclerosis-to-aortic-stenosis
© 2011 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
